Home › Funds › Capital Research Global Investors › GILD

Capital Research Global Investors position in GILD

GILEAD SCIENCES INC · Health Care

Capital Research Global Investors reported holding 23,980,766 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$3.57B, representing 0.51% of its reported portfolio and ranking #45 among its reported holdings. Capital Research Global Investors has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)23.98M sh
Reported value held$3.57B
Portfolio Weight0.51%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Capital Research Global Investors's GILD position evolved

Capital Research Global Investors first disclosed a stake in GILD in Q3 2023 at 57,913,708 shares (US$4.34B). The position peaked in Q1 2025 at 54,610,370 shares, worth US$6.12B. Across 13 filings, Capital Research Global Investors increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 23,980,766 shares valued at US$3.57B — an increase of 4,587,470 shares quarter over quarter.. Notable position changes include a 43% trim in Q2 2025 (shares were roughly flat over the following quarter), a 29% trim in Q2 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 57.91M $4.34B New
Q4 2023 59.66M $4.83B Add
Q1 2024 61.25M $4.49B Add
Q2 2024 60.43M $4.15B Reduce
Q3 2024 61.80M $5.18B Add
Q4 2024 57.95M $5.35B Reduce
Q1 2025 54.61M $6.12B Reduce
Q2 2025 31.10M $3.45B Reduce
Q3 2025 30.01M $3.33B Reduce
Q4 2025 25.31M $3.11B Reduce
Q1 2026 27.13M $3.78B Add
Q2 2026 19.39M $2.45B Reduce
Q3 2026 23.98M $3.57B Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 33 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has Capital Research Global Investors held GILD?

Capital Research Global Investors has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Capital Research Global Investors's current position in GILD?

As of Q3 2026, Capital Research Global Investors holds 23.98M shares of GILD (GILEAD SCIENCES INC), valued at $3.57B, representing 0.51% of its reported portfolio and ranking #45.

Has Capital Research Global Investors been buying or selling GILD?

In the latest 13F filing (Q3 2026), Capital Research Global Investors increased its position in GILD. The position peaked in Q1 2025 at 54.61M shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.